US5179017A
(en)
|
1980-02-25 |
1993-01-12 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
US4634665A
(en)
|
1980-02-25 |
1987-01-06 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
US4399216A
(en)
|
1980-02-25 |
1983-08-16 |
The Trustees Of Columbia University |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
US5156840A
(en)
|
1982-03-09 |
1992-10-20 |
Cytogen Corporation |
Amine-containing porphyrin derivatives
|
US5057313A
(en)
|
1986-02-25 |
1991-10-15 |
The Center For Molecular Medicine And Immunology |
Diagnostic and therapeutic antibody conjugates
|
EP0307434B2
(en)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Altered antibodies
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
IL162181A
(en)
|
1988-12-28 |
2006-04-10 |
Pdl Biopharma Inc |
A method of producing humanized immunoglubulin, and polynucleotides encoding the same
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
EP0940468A1
(en)
|
1991-06-14 |
1999-09-08 |
Genentech, Inc. |
Humanized antibody variable domain
|
ATE207080T1
(de)
|
1991-11-25 |
2001-11-15 |
Enzon Inc |
Multivalente antigen-bindende proteine
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
US5521184A
(en)
|
1992-04-03 |
1996-05-28 |
Ciba-Geigy Corporation |
Pyrimidine derivatives and processes for the preparation thereof
|
US5827690A
(en)
|
1993-12-20 |
1998-10-27 |
Genzyme Transgenics Corporatiion |
Transgenic production of antibodies in milk
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
ATE219517T1
(de)
|
1995-08-18 |
2002-07-15 |
Morphosys Ag |
Protein-/(poly)peptidbibliotheken
|
DE19629378A1
(de)
|
1996-07-20 |
1998-01-29 |
Boehringer Ingelheim Kg |
Neue Triazolopurine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
JP4195729B2
(ja)
*
|
1997-03-24 |
2008-12-10 |
協和醗酵工業株式会社 |
[1,2,4]トリアゾロ[1,5−c]ピリミジン誘導体
|
PT1107964E
(pt)
|
1998-08-11 |
2010-06-11 |
Novartis Ag |
Derivados de isoquinolina com actividade inibidora da angiogénese
|
IL142128A0
(en)
|
1998-09-22 |
2002-03-10 |
Kyowa Hakko Kogyo Kk |
[1,2,4] triazolo [1,5-c] pyrimidine derivatives
|
US6133031A
(en)
|
1999-08-19 |
2000-10-17 |
Isis Pharmaceuticals Inc. |
Antisense inhibition of focal adhesion kinase expression
|
GB9905075D0
(en)
|
1999-03-06 |
1999-04-28 |
Zeneca Ltd |
Chemical compounds
|
CA2944644C
(en)
|
1999-05-07 |
2017-08-22 |
Genentech, Inc. |
Use of rituximab to treat pemphigus
|
JP4896327B2
(ja)
|
1999-08-23 |
2012-03-14 |
ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド |
Pd−1、b7−4の受容体、およびその使用
|
BR0013542A
(pt)
|
1999-08-23 |
2002-05-14 |
Dana Farber Cancer Inst Inc |
Moléculas b7-4 e usos para as mesmas
|
US6355653B1
(en)
|
1999-09-06 |
2002-03-12 |
Hoffmann-La Roche Inc. |
Amino-triazolopyridine derivatives
|
US6803192B1
(en)
|
1999-11-30 |
2004-10-12 |
Mayo Foundation For Medical Education And Research |
B7-H1, a novel immunoregulatory molecule
|
CA3016482A1
(en)
|
1999-11-30 |
2001-06-07 |
Mayo Foundation For Medical Education And Research |
B7-h1, a novel immunoregulatory molecule
|
GB0004890D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
MXPA02010507A
(es)
|
2000-04-25 |
2003-05-14 |
Idec Pharma Corp |
Administracion intratecal de rituximab para el tratamiento de linfomas del sistema nervioso central.
|
AU6808901A
(en)
|
2000-05-26 |
2001-12-11 |
Schering Corp |
Adenosine a2a receptor antagonists
|
JP4188078B2
(ja)
|
2000-06-28 |
2008-11-26 |
スミスクライン ビーチャム ピー エル シー |
湿式粉砕法
|
JP4251868B2
(ja)
|
2000-08-11 |
2009-04-08 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
2−アミノピリジン化合物および医薬用途
|
DE60230482D1
(de)
|
2001-01-17 |
2009-02-05 |
Intreat Pty Ltd |
Antikörper gegen nichtfunktionelle p 2 x 7 rezeptoren, diagnose und behandlung von krebs und anderen leiden
|
WO2002086083A2
(en)
|
2001-04-20 |
2002-10-31 |
Mayo Foundation For Medical Education And Research |
Methods of enhancing cell responsiveness
|
US6806268B2
(en)
|
2001-05-30 |
2004-10-19 |
Alteon, Inc. |
Method for treating glaucoma V
|
WO2002096363A2
(en)
|
2001-05-30 |
2002-12-05 |
Alteon, Inc. |
Method for treating fibrotic diseases or other indications
|
EA007983B1
(ru)
|
2001-09-19 |
2007-02-27 |
Авентис Фарма С.А. |
Индолизины в качестве ингибиторов киназных белков
|
AU2002334969A1
(en)
|
2001-10-09 |
2003-04-22 |
Sylvie Barchechath |
Use of stat-6 inhibitors as therapeutic agents
|
WO2003037347A1
(en)
|
2001-10-30 |
2003-05-08 |
Novartis Ag |
Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
|
WO2003042402A2
(en)
|
2001-11-13 |
2003-05-22 |
Dana-Farber Cancer Institute, Inc. |
Agents that modulate immune cell activation and methods of use thereof
|
US6921762B2
(en)
*
|
2001-11-16 |
2005-07-26 |
Amgen Inc. |
Substituted indolizine-like compounds and methods of use
|
AR038366A1
(es)
|
2001-11-30 |
2005-01-12 |
Schering Corp |
Compuestos de 1,2,4-triazolo [1,5-c] pirimidinas sustituidas, antagonistas del receptor de adenosina a2a, composiciones farmaceuticas, el uso de dichos compuestos para la manufactura de un medicamento para el tratamiento de enfermedades del sistema nervioso central y un kit que comprende combinacion
|
ME00230B
(me)
|
2002-01-22 |
2011-02-10 |
|
2-(piridin -2-ilamino)-pirido(2,3-d) pirimidin-7-oni
|
JPWO2003068776A1
(ja)
|
2002-02-15 |
2005-06-02 |
協和醗酵工業株式会社 |
[1,2,4]トリアゾロ[1,5−c]ピリミジン誘導体
|
PE20040522A1
(es)
|
2002-05-29 |
2004-09-28 |
Novartis Ag |
Derivados de diarilurea dependientes de la cinasa de proteina
|
GB0215676D0
(en)
|
2002-07-05 |
2002-08-14 |
Novartis Ag |
Organic compounds
|
US20060058320A1
(en)
|
2002-09-24 |
2006-03-16 |
Kyowa Hakko Kogyo Co., Ltd. |
[1,2,4] Triazolo[1,5-c]pyrimidine derivatives
|
AR042052A1
(es)
|
2002-11-15 |
2005-06-08 |
Vertex Pharma |
Diaminotriazoles utiles como inhibidores de proteinquinasas
|
UA80767C2
(en)
|
2002-12-20 |
2007-10-25 |
Pfizer Prod Inc |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
ES2367430T3
(es)
|
2002-12-23 |
2011-11-03 |
Wyeth Llc |
Anticuerpos contra pd-1 y sus usos.
|
CA2512729C
(en)
|
2003-01-09 |
2014-09-16 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant fc regions and methods of using same
|
AU2004205631A1
(en)
|
2003-01-16 |
2004-08-05 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
WO2004072266A2
(en)
|
2003-02-13 |
2004-08-26 |
Kalobios Inc. |
Antibody affinity engineering by serial epitope-guided complementarity replacement
|
GB0303910D0
(en)
|
2003-02-20 |
2003-03-26 |
Merck Sharp & Dohme |
Therapeutic agents
|
WO2004079013A1
(en)
|
2003-03-03 |
2004-09-16 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
|
GB0305929D0
(en)
|
2003-03-14 |
2003-04-23 |
Novartis Ag |
Organic compounds
|
CA2517888C
(en)
|
2003-03-14 |
2012-05-01 |
Ono Pharmaceutical Co., Ltd. |
Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
|
AR043633A1
(es)
|
2003-03-20 |
2005-08-03 |
Schering Corp |
Ligandos de receptores de canabinoides
|
ATE418555T1
(de)
|
2003-04-09 |
2009-01-15 |
Biogen Idec Inc |
A2a-adenosinrezeptorantagonisten
|
EP1615931A1
(en)
|
2003-04-09 |
2006-01-18 |
Biogen Idec MA Inc. |
Triazolopyrazines and methods of making and using the same
|
EP1618109A2
(en)
*
|
2003-04-09 |
2006-01-25 |
Biogen Idec MA Inc. |
Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists
|
PL1613350T3
(pl)
|
2003-04-09 |
2009-08-31 |
Genentech Inc |
Leczenie choroby autoimmunologicznej u pacjenta z nieodpowiednią odpowiedzią na leczenie inhibitorem TNFα
|
EA200501924A1
(ru)
|
2003-06-10 |
2006-06-30 |
Киова Хакко Когио Ко., Лтд. |
Способ лечения тревожного расстройства
|
CA2528551A1
(en)
|
2003-06-13 |
2005-01-13 |
Biogen Idec Ma Inc. |
Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
|
BRPI0413540A
(pt)
|
2003-08-14 |
2006-10-10 |
Hoffmann La Roche |
moduladores gabanérgicos
|
CN1871259A
(zh)
|
2003-08-22 |
2006-11-29 |
比奥根艾迪克Ma公司 |
具有改变的效应物功能的经改进的抗体和制备它的方法
|
EP1663204B1
(en)
|
2003-08-29 |
2014-05-07 |
Exelixis, Inc. |
C-kit modulators and methods of use
|
PE20050952A1
(es)
|
2003-09-24 |
2005-12-19 |
Novartis Ag |
Derivados de isoquinolina como inhibidores de b-raf
|
GB0403819D0
(en)
|
2004-02-20 |
2004-03-24 |
Merck Sharp & Dohme |
New compounds
|
EP1737459B1
(en)
|
2004-03-19 |
2009-08-05 |
Warner-Lambert Company LLC |
Imidazopyridine and imidazopyrimidine derivatives as antibacterial agents
|
US7306631B2
(en)
|
2004-03-30 |
2007-12-11 |
The Procter & Gamble Company |
Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
|
JP2008501714A
(ja)
|
2004-06-04 |
2008-01-24 |
武田薬品工業株式会社 |
ジペプチジルペプチダーゼインヒビター
|
WO2006000922A2
(en)
|
2004-06-23 |
2006-01-05 |
Idenix (Cayman) Limited |
5-aza-7-deazapurine derivatives for treating infections with flaviviridae
|
WO2006004702A1
(en)
|
2004-06-25 |
2006-01-12 |
Amgen Inc. |
Condensed triazoles and indazoles useful in treating citokines mediated diseases and other diseases
|
SG156643A1
(en)
|
2004-10-15 |
2009-11-26 |
Verisign Inc |
One time password
|
EP1812439B2
(en)
|
2004-10-15 |
2017-12-06 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
US20060211739A1
(en)
|
2005-02-08 |
2006-09-21 |
Arturo Perez-Medrano |
Use of selective P2X7 receptor antagonists
|
EP1896582A4
(en)
|
2005-05-09 |
2009-04-08 |
Ono Pharmaceutical Co |
HUMAN MONOCLONAL ANTIBODIES FOR PROGRAMMED DEATH 1 (MP-1) AND METHODS FOR TREATING CANCER USING ANTI-MP-1 ANTIBODIES ALONE OR ASSOCIATED WITH OTHER IMMUNOTHERAPIES
|
KR20080025066A
(ko)
|
2005-05-18 |
2008-03-19 |
바이오겐 아이덱 인크. |
섬유성 상태의 치료 방법
|
JPWO2006129626A1
(ja)
|
2005-05-30 |
2009-01-08 |
協和醗酵工業株式会社 |
[1,2,4]トリアゾロ[1,5−c]ピリミジン誘導体の製造法
|
ATE556712T1
(de)
|
2005-06-07 |
2012-05-15 |
Kyowa Hakko Kirin Co Ltd |
A2a antagonisten zur behandlung von motorischen störungen
|
US7452892B2
(en)
|
2005-06-17 |
2008-11-18 |
Bristol-Myers Squibb Company |
Triazolopyrimidine cannabinoid receptor 1 antagonists
|
JP4986451B2
(ja)
|
2005-06-30 |
2012-07-25 |
信一郎 礒部 |
マーキング剤
|
CA2612241C
(en)
|
2005-07-01 |
2018-11-06 |
Medarex, Inc. |
Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
|
WO2007011759A2
(en)
|
2005-07-15 |
2007-01-25 |
Kalypsys, Inc. |
Inhibitors of mitotic kinesin
|
US7709468B2
(en)
|
2005-09-02 |
2010-05-04 |
Abbott Laboratories |
Imidazo based heterocycles
|
EP1945644A2
(en)
|
2005-11-10 |
2008-07-23 |
Schering Corporation |
Imidazopyrazines as protein kinase inhibitors
|
PT2385053E
(pt)
|
2005-11-17 |
2013-12-17 |
Osi Pharm Inc |
Intermediários para a preparação de compostos bicíclicos condensados como inibidores mtor
|
EP2233472B1
(en)
|
2006-03-28 |
2014-01-15 |
Atir Holding S.A. |
Heterocyclic compounds and uses thereof in the treatment of sexual disorders
|
CA2653506A1
(en)
|
2006-05-31 |
2007-12-06 |
Galapagos Nv. |
Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases
|
US8008332B2
(en)
|
2006-05-31 |
2011-08-30 |
Takeda San Diego, Inc. |
Substituted indazoles as glucokinase activators
|
EP2037905B1
(en)
|
2006-06-23 |
2013-05-01 |
Radius Health, Inc. |
Treatment of vasomotor symptoms with selective estrogen receptor modulators
|
AR061625A1
(es)
|
2006-06-23 |
2008-09-10 |
Incyte Corp |
Derivados de purinona como agonistas de hm74a
|
JP5382692B2
(ja)
|
2006-07-10 |
2014-01-08 |
学校法人藤田学園 |
抗体の分類法、抗原の同定法、抗体又は抗体セットの取得法、抗体パネルの作成法、並びに抗体又は抗体セット及びその用途
|
WO2008011557A2
(en)
|
2006-07-20 |
2008-01-24 |
Borchardt Allen J |
Heteroaryl inhibitors of rho kinase
|
DE102006041292A1
(de)
|
2006-09-01 |
2008-03-06 |
Henkel Kgaa |
Wasserstoffperoxid-Aktivierung mit N-Heterocyclen
|
WO2008037607A1
(de)
|
2006-09-25 |
2008-04-03 |
Basf Se |
Carbonylgruppen-enthaltende heterocyclische verbindungen und deren verwendung zur bekämpfung von phytopathogenen pilzen
|
WO2008056176A1
(en)
|
2006-11-10 |
2008-05-15 |
Scottish Biomedical Limited |
Pyrazolopyrimidines as phosphodiesterase inhibitors
|
WO2008070599A1
(en)
|
2006-12-05 |
2008-06-12 |
Chung-Ming Sun |
Indazole compounds
|
DE102007012645A1
(de)
|
2007-03-16 |
2008-09-18 |
Bayer Healthcare Ag |
Substituierte Imidazo- und Triazolopyrimidine
|
WO2008124153A1
(en)
|
2007-04-10 |
2008-10-16 |
H. Lundbeck A/S |
Heteroaryl amide analogues as p2x7 antagonists
|
US8039505B2
(en)
|
2007-04-11 |
2011-10-18 |
University Of Utah Research Foundation |
Compounds for modulating T-cells
|
EP2155747B1
(en)
|
2007-05-10 |
2012-10-24 |
GE Healthcare Limited |
Imidazol (1,2-a)pyridines and related compounds with activity at cannabinoid cb2 receptors
|
US8133895B2
(en)
|
2007-05-10 |
2012-03-13 |
Janssen Pharmaceutica N.V. |
Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases
|
HUP0700395A2
(en)
|
2007-06-07 |
2009-03-02 |
Sanofi Aventis |
Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates
|
PL2170959T3
(pl)
|
2007-06-18 |
2014-03-31 |
Merck Sharp & Dohme |
Przeciwciała przeciwko ludzkiemu receptorowi programowanej śmierci PD-1
|
WO2009010530A1
(en)
|
2007-07-18 |
2009-01-22 |
Novartis Ag |
Bicyclic heteroaryl compounds and their use as kinase inhibitors
|
GB0715087D0
(en)
|
2007-08-03 |
2007-09-12 |
Summit Corp Plc |
Drug combinations for the treatment of duchenne muscular dystrophy
|
MX2010001650A
(es)
|
2007-08-10 |
2010-08-02 |
Glaxosmithkline Llc |
Entidades quimicas biciclicas que contienen nitrogeno para el tratamiento de infecciones virales.
|
US8062852B2
(en)
|
2007-10-01 |
2011-11-22 |
The Children's Hospital And Regional Medical Center |
Detection and treatment of autoimmune disorders
|
GB0719803D0
(en)
|
2007-10-10 |
2007-11-21 |
Cancer Rec Tech Ltd |
Therapeutic compounds and their use
|
WO2009050228A2
(en)
|
2007-10-18 |
2009-04-23 |
Novartis Ag |
Csf-1r inhibitors for treatment of cancer and bone diseases
|
US20090118301A1
(en)
|
2007-11-02 |
2009-05-07 |
Arbor Vita Corporation |
Compositions and Methods for Treating Cancer
|
CA2704645A1
(en)
|
2007-11-09 |
2009-05-14 |
The Salk Institute For Biological Studies |
Non-nucleoside reverse transcriptase inhibitors
|
PE20091074A1
(es)
|
2007-12-13 |
2009-07-26 |
Bayer Healthcare Ag |
Triazolotriazinas y triazolopirazinas y su uso
|
EP2231661A1
(en)
|
2007-12-19 |
2010-09-29 |
Amgen, Inc. |
Inhibitors of pi3 kinase
|
EP2231656A1
(en)
|
2007-12-19 |
2010-09-29 |
Amgen Inc. |
Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
WO2009114870A2
(en)
|
2008-03-14 |
2009-09-17 |
Intellikine, Inc. |
Kinase inhibitors and methods of use
|
WO2009117421A2
(en)
|
2008-03-17 |
2009-09-24 |
Kalypsys, Inc. |
Heterocyclic modulators of gpr119 for treatment of disease
|
KR101632450B1
(ko)
|
2008-03-21 |
2016-06-21 |
엔쏜 인코포레이티드 |
다작용기성 화합물을 이용한 적층체에 대한 금속의 접착 촉진
|
US20090281089A1
(en)
|
2008-04-11 |
2009-11-12 |
Genentech, Inc. |
Pyridyl inhibitors of hedgehog signalling
|
JPWO2009128520A1
(ja)
|
2008-04-18 |
2011-08-04 |
塩野義製薬株式会社 |
Pi3k阻害活性を有する複素環化合物
|
TWI473614B
(zh)
|
2008-05-29 |
2015-02-21 |
Kyowa Hakko Kirin Co Ltd |
Anti-analgesic inhibitors
|
AU2009274876C1
(en)
|
2008-07-23 |
2016-08-18 |
Kyowa Kirin Co., Ltd. |
Therapeutic agent for migraine
|
WO2010033906A2
(en)
|
2008-09-19 |
2010-03-25 |
President And Fellows Of Harvard College |
Efficient induction of pluripotent stem cells using small molecule compounds
|
WO2010032874A1
(ja)
|
2008-09-19 |
2010-03-25 |
住友化学株式会社 |
農業用組成物
|
CA2998281C
(en)
|
2008-09-26 |
2022-08-16 |
Dana-Farber Cancer Institute, Inc. |
Human anti-pd-1 antobodies and uses therefor
|
HRP20240240T1
(hr)
|
2008-12-09 |
2024-04-26 |
F. Hoffmann - La Roche Ag |
Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice
|
JO2885B1
(en)
|
2008-12-22 |
2015-03-15 |
ايلي ليلي اند كومباني |
Protein kinase inhibitors
|
MX2011006333A
(es)
|
2008-12-23 |
2011-06-27 |
Abbott Lab |
Compuestos antivirales.
|
CN102264737A
(zh)
|
2008-12-23 |
2011-11-30 |
雅培制药有限公司 |
抗病毒化合物
|
EP2210891A1
(en)
|
2009-01-26 |
2010-07-28 |
Domain Therapeutics |
New adenosine receptor ligands and uses thereof
|
EP2393835B1
(en)
|
2009-02-09 |
2017-04-05 |
Université d'Aix-Marseille |
Pd-1 antibodies and pd-l1 antibodies and uses thereof
|
KR20100101055A
(ko)
|
2009-03-07 |
2010-09-16 |
주식회사 메디젠텍 |
세포핵에서 세포질로의 gsk3의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동 관련 질환의 치료 또는 예방용 약학적 조성물
|
US8846673B2
(en)
|
2009-08-11 |
2014-09-30 |
Bristol-Myers Squibb Company |
Azaindazoles as kinase inhibitors and use thereof
|
GEP201706639B
(en)
|
2009-08-17 |
2017-03-27 |
Intellikine Llc |
Heterocyclic compounds and uses thereof
|
EP2509983B1
(en)
|
2009-11-16 |
2014-09-17 |
Merck Sharp & Dohme Corp. |
FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY
|
JP2013512251A
(ja)
|
2009-11-24 |
2013-04-11 |
アンプリミューン、インコーポレーテッド |
Pd−l1/pd−l2の同時阻害
|
WO2011078143A1
(ja)
|
2009-12-22 |
2011-06-30 |
塩野義製薬株式会社 |
ピリミジン誘導体およびそれらを含有する医薬組成物
|
WO2011082400A2
(en)
|
2010-01-04 |
2011-07-07 |
President And Fellows Of Harvard College |
Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
|
EP2347769A1
(en)
|
2010-01-20 |
2011-07-27 |
Glycotope GmbH |
Cancer stem cell markers and uses thereof
|
US20110190269A1
(en)
|
2010-02-01 |
2011-08-04 |
Karlheinz Baumann |
Gamma secretase modulators
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
TW201200518A
(en)
|
2010-03-10 |
2012-01-01 |
Kalypsys Inc |
Heterocyclic inhibitors of histamine receptors for the treatment of disease
|
JP5944837B2
(ja)
|
2010-03-18 |
2016-07-05 |
インスティチュート・パスツール・コリアInstitut Pasteur Korea |
抗感染化合物
|
UY33304A
(es)
|
2010-04-02 |
2011-10-31 |
Amgen Inc |
Compuestos heterocíclicos y sus usos
|
GB201007187D0
(en)
|
2010-04-29 |
2010-06-09 |
Iti Scotland Ltd |
Ubiquitination modulators
|
WO2011153588A1
(en)
|
2010-06-10 |
2011-12-15 |
Biota Scientific Management Pty Ltd |
Viral polymerase inhibitors
|
US20120083498A1
(en)
|
2010-06-17 |
2012-04-05 |
Fatah Kashanchi |
Modulators of Viral Transcription, and Methods and Compositions Therewith
|
JP2013532153A
(ja)
|
2010-06-18 |
2013-08-15 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド |
慢性免疫病に対する免疫治療のためのtim−3およびpd−1に対する二重特異性抗体
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
ES2614128T3
(es)
|
2010-08-27 |
2017-05-29 |
Merck Patent Gmbh |
Derivados de triazolopirazina
|
KR101929593B1
(ko)
|
2010-10-25 |
2018-12-14 |
쥐원 쎄라퓨틱스, 인크. |
Cdk 억제제
|
JP2014503528A
(ja)
|
2010-12-14 |
2014-02-13 |
エレクトロプホレトイクス リミテッド |
カゼインキナーゼ1δ(CK1δ)阻害剤及びタウオパチーなどの神経変性疾患の治療におけるその使用
|
CN107141309A
(zh)
|
2011-01-11 |
2017-09-08 |
桑诺维恩药品公司 |
杂芳基化合物及其使用方法
|
WO2012116237A2
(en)
|
2011-02-23 |
2012-08-30 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
ES2543569T3
(es)
|
2011-03-23 |
2015-08-20 |
Amgen Inc. |
Inhibidores duales tricíclicos condensados de CDK 4/6 y FLT3
|
WO2012143796A2
(en)
|
2011-04-21 |
2012-10-26 |
Institut Pasteur Korea |
Anti-inflammation compounds
|
WO2012147890A1
(ja)
|
2011-04-27 |
2012-11-01 |
持田製薬株式会社 |
新規アゾール誘導体
|
DE102011111400A1
(de)
|
2011-08-23 |
2013-02-28 |
Merck Patent Gmbh |
Bicyclische heteroaromatische Verbindungen
|
EP2604265A1
(en)
|
2011-12-17 |
2013-06-19 |
Royal College of Surgeons in Ireland (RCSI) |
P2x7 antagonists as frontline or adjunctive treatment against status epilepticus
|
WO2013106254A1
(en)
|
2012-01-11 |
2013-07-18 |
Dow Agrosciences Llc |
Pesticidal compositions and processes related thereto
|
JP5992096B2
(ja)
|
2012-05-30 |
2016-09-14 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
Pde10阻害剤としてのトリアゾロ化合物
|
US9260436B2
(en)
|
2012-06-22 |
2016-02-16 |
Sumitomo Chemical Company, Limited |
Fused heterocyclic compound
|
RU2015104103A
(ru)
|
2012-07-27 |
2016-09-20 |
Биал - Портела Энд К, С.А. |
Способ синтеза замещенных соединений мочевины
|
WO2014078479A2
(en)
|
2012-11-14 |
2014-05-22 |
The Board Of Regents Of The University Of Texas System |
INHIBITION OF HIF-2α HETERODIMERIZATION WITH HIF1β (ARNT)
|
WO2014126580A1
(en)
|
2013-02-15 |
2014-08-21 |
Dow Agrosciences Llc |
Pesticidal compositions and processes related thereto
|
ES2705247T3
(es)
|
2013-03-14 |
2019-03-22 |
Univ Columbia |
4-fenilpiperidinas, su preparación y uso
|
US9090697B2
(en)
|
2013-03-15 |
2015-07-28 |
Bayer Healthcare Llc |
Methods for treating bleeding disorders
|
WO2014153424A1
(en)
|
2013-03-19 |
2014-09-25 |
La Jolla Institute For Allergy And Immunology |
Reducing diabetes in patients receiving hmg-coa reductase inhibitors (statins)
|
CN105611835A
(zh)
|
2013-07-25 |
2016-05-25 |
达纳-法伯癌症研究所股份有限公司 |
转录因子抑制剂及其用途
|
WO2015157955A1
(en)
|
2014-04-17 |
2015-10-22 |
Abbvie Inc. |
Heterocyclic btk inhibit ors
|
WO2016007722A1
(en)
|
2014-07-10 |
2016-01-14 |
Incyte Corporation |
Triazolopyridines and triazolopyrazines as lsd1 inhibitors
|
EP3309174B1
(en)
|
2014-07-11 |
2022-05-11 |
Ventana Medical Systems, Inc. |
Anti-pd-l1 antibodies and diagnostic uses thereof
|
JP2017531037A
(ja)
|
2014-10-06 |
2017-10-19 |
フラットレー ディスカバリー ラブ,エルエルシー |
トリアゾロピリジン化合物および嚢胞性線維症の治療のための方法
|
US20180030144A1
(en)
|
2014-10-10 |
2018-02-01 |
Innate Pharma |
Cd73 blockade
|
CA2957813A1
(en)
|
2014-10-10 |
2016-04-14 |
Innate Pharma |
Cd73 blockade
|
AU2015345202B2
(en)
|
2014-11-10 |
2021-05-13 |
Medimmune Limited |
Binding molecules specific for CD73 and uses thereof
|
EP3789403A1
(en)
|
2014-11-11 |
2021-03-10 |
MedImmune Limited |
Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof
|
US10100129B2
(en)
|
2014-11-21 |
2018-10-16 |
Bristol-Myers Squibb Company |
Antibodies against CD73 and uses thereof
|
BR112017015870B1
(pt)
|
2015-02-12 |
2021-11-16 |
Nissan Chemical Corporation |
Composto heterocíclico condensado, pesticida, produto químico agrícola, agente de tratamento de sementes e do solo
|
ES2838977T3
(es)
|
2015-03-06 |
2021-07-02 |
Pharmakea Inc |
Inhibidores de la lisil oxidasa fluorada tipo 2 y usos de los mismos
|
TWI714567B
(zh)
|
2015-04-03 |
2021-01-01 |
美商英塞特公司 |
作為lsd1抑制劑之雜環化合物
|
AU2016298227B9
(en)
|
2015-07-30 |
2019-10-31 |
Macrogenics, Inc. |
PD-1-binding molecules and methods of use thereof
|
US11130817B2
(en)
|
2015-10-12 |
2021-09-28 |
Innate Pharma |
CD73 blocking agents
|
EP3365340B1
(en)
|
2015-10-19 |
2022-08-10 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
MX2018006207A
(es)
|
2015-11-19 |
2018-09-05 |
Incyte Corp |
Compuestos heterociclicos como inmunomoduladores.
|
AU2016366548B2
(en)
|
2015-12-09 |
2023-12-14 |
Bioatla, Llc |
Humanized anti-CD73 antibodies
|
US20170174671A1
(en)
|
2015-12-17 |
2017-06-22 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
CN116514715A
(zh)
|
2015-12-22 |
2023-08-01 |
因赛特公司 |
作为免疫调节剂的杂环化合物
|
EA201891509A1
(ru)
|
2015-12-24 |
2019-01-31 |
Корвус Фармасьютикалз, Инк. |
Способы лечения рака
|
UA119835C2
(uk)
|
2016-02-24 |
2019-08-12 |
Пфайзер Інк. |
ПОХІДНІ ПІРАЗОЛО[1,5-а]ПІРАЗИН-4-ІЛУ ЯК JAK-ІНГІБІТОРИ
|
EP4219449A3
(en)
|
2016-03-16 |
2023-10-11 |
Kura Oncology, Inc. |
Substituted indole derivatives and methods of preparation thereof
|
US20170320875A1
(en)
|
2016-05-06 |
2017-11-09 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
WO2017205464A1
(en)
|
2016-05-26 |
2017-11-30 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
AU2017281285C1
(en)
|
2016-06-20 |
2022-05-12 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
WO2017223414A1
(en)
*
|
2016-06-24 |
2017-12-28 |
Incyte Corporation |
HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
|
WO2018004478A1
(en)
|
2016-06-29 |
2018-01-04 |
Hayat Kimya San. A. Ş. |
An improved method of soft nonwoven fabric production
|
EP3481869A4
(en)
|
2016-07-11 |
2020-02-26 |
Corvus Pharmaceuticals, Inc. |
ANTI-CD73 ANTIBODY
|
EP3484866B1
(en)
|
2016-07-14 |
2022-09-07 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
MA46045A
(fr)
|
2016-08-29 |
2021-04-28 |
Incyte Corp |
Composés hétérocycliques utilisés comme immunomodulateurs
|
RS62256B1
(sr)
|
2016-09-02 |
2021-09-30 |
Cyclerion Therapeutics Inc |
Fuzionisani biciklični sgc stimulatori
|
EP3556773A4
(en)
|
2016-12-13 |
2020-08-19 |
Astellas Pharma Inc. |
ANTIBODIES TO HUMAN CD73
|
CR20190317A
(es)
|
2016-12-22 |
2019-09-13 |
Incyte Corp |
Compuestos inmunomodulares y métodos de uso
|
MY197635A
(en)
|
2016-12-22 |
2023-06-29 |
Incyte Corp |
Benzooxazole derivatives as immunomodulators
|
EP3558963B1
(en)
|
2016-12-22 |
2022-03-23 |
Incyte Corporation |
Bicyclic heteroaromatic compounds as immunomodulators
|
ES2899402T3
(es)
|
2016-12-22 |
2022-03-11 |
Incyte Corp |
Derivados de piridina como inmunomoduladores
|
US20180177784A1
(en)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
EP3558989B1
(en)
|
2016-12-22 |
2021-04-14 |
Incyte Corporation |
Triazolo[1,5-a]pyridine derivatives as immunomodulators
|
SG11201906209SA
(en)
|
2017-01-23 |
2019-08-27 |
Revolution Medicines Inc |
Bicyclic compounds as allosteric shp2 inhibitors
|
WO2018137598A1
(en)
|
2017-01-24 |
2018-08-02 |
I-Mab |
Anti-cd73 antibodies and uses thereof
|
RU2764655C2
(ru)
*
|
2017-03-16 |
2022-01-19 |
Цзянсу Хэнжуй Медицин Ко., Лтд. |
ПРОИЗВОДНОЕ ГЕТЕРОАРИЛ[4,3-с]ПИРИМИДИН-5-АМИНА, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО МЕДИЦИНСКИЕ ПРИМЕНЕНИЯ
|
US20210107989A1
(en)
|
2017-04-04 |
2021-04-15 |
Corvus Pharmaceuticals, Inc. |
Methods for treating cd73hi tumors
|
PT3611174T
(pt)
*
|
2017-04-07 |
2022-07-07 |
Medshine Discovery Inc |
Derivado de [1,2,4]triazolo[1,5-c]pirimidina como inibidor do recetor a2a
|
US11530273B2
(en)
|
2017-05-23 |
2022-12-20 |
Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Anti-CD73 monoclonal antibody, encoding nucleic acids and method for producing
|
US11542248B2
(en)
|
2017-06-08 |
2023-01-03 |
Kura Oncology, Inc. |
Methods and compositions for inhibiting the interaction of menin with MLL proteins
|
EP3642240A1
(en)
|
2017-06-22 |
2020-04-29 |
Novartis AG |
Antibody molecules to cd73 and uses thereof
|
SG11201912473PA
(en)
|
2017-06-22 |
2020-01-30 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
JP2020525472A
(ja)
|
2017-06-30 |
2020-08-27 |
ライブ・セラピューティクス・スプウカ・アクツィーナRyvu Therapeutics S.A. |
アデノシンa2a受容体のイミダゾ[1,2−a]ピラジン調節剤
|
CN109535161B
(zh)
*
|
2017-09-22 |
2021-09-03 |
江苏恒瑞医药股份有限公司 |
三唑并嘧啶类衍生物、其制备方法及其在医药上的应用
|
BR112020007967A2
(pt)
|
2017-10-24 |
2020-10-20 |
Bayer Aktiengesellschaft |
imidazopiridina amidas substituídas e uso das mesmas
|
AU2018368731A1
(en)
|
2017-11-16 |
2020-05-14 |
Novartis Ag |
Combination therapies
|
BR112020015666A2
(pt)
|
2018-01-31 |
2021-02-23 |
Aptinyx Inc. |
moduladores de espiro-lactamas de receptores nmda e usos dos mesmos
|
PE20210455A1
(es)
|
2018-01-31 |
2021-03-08 |
Aptinyx Inc |
Moduladores del receptor nmda espiro-lactama y usos de los mismos
|
EP3752251A1
(en)
|
2018-02-17 |
2020-12-23 |
AstraZeneca AB |
Arginase inhibitors and methods of use thereof
|
BR112020017421A2
(pt)
|
2018-02-27 |
2020-12-22 |
Incyte Corporation |
Imidazopirimidinas e triazolopirimidinas como inibidores de a2a/a2b
|
WO2019170131A1
(zh)
|
2018-03-07 |
2019-09-12 |
复旦大学 |
靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途
|
KR20200128542A
(ko)
|
2018-03-09 |
2020-11-13 |
페인스 테라퓨틱스 인코포레이티드 |
항-cd73 항체 및 이의 용도
|
US11692042B2
(en)
|
2018-03-09 |
2023-07-04 |
Agenus Inc. |
Anti-CD73 antibodies and methods of use thereof
|
PT3774791T
(pt)
|
2018-03-30 |
2023-03-03 |
Incyte Corp |
Compostos heterocíclicos como imunomoduladores
|
US11220510B2
(en)
|
2018-04-09 |
2022-01-11 |
Incyte Corporation |
Pyrrole tricyclic compounds as A2A / A2B inhibitors
|
KR20200142542A
(ko)
|
2018-04-12 |
2020-12-22 |
브리스톨-마이어스 스큅 컴퍼니 |
Cd73 길항제 항체 및 pd-1/pd-l1 축 길항제 항체에 의한 항암 조합 요법
|
PE20211918A1
(es)
|
2018-05-11 |
2021-09-28 |
Incyte Corp |
Derivados de tetrahidro-imidazo[4,5-c]piridin como inmunomoduladores de pd-l1
|
MA52940A
(fr)
|
2018-05-18 |
2021-04-28 |
Incyte Corp |
Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
|
CA3104467A1
(en)
|
2018-06-20 |
2019-12-26 |
Incyte Corporation |
Anti-pd-1 antibodies and uses thereof
|
GEP20237560B
(en)
|
2018-07-05 |
2023-10-25 |
Incyte Corp |
Fused pyrazine derivatives as a2a / a2b inhibitors
|
PE20211380A1
(es)
|
2018-08-13 |
2021-07-27 |
Hoffmann La Roche |
Nuevos compuestos heterociclicos como inhibidores de monoacilglicerol lipasa
|
AU2019322538B2
(en)
|
2018-08-13 |
2021-09-30 |
F. Hoffmann-La Roche Ag |
New heterocyclic compounds as monoacylglycerol lipase inhibitors
|
GB201813678D0
(en)
|
2018-08-22 |
2018-10-03 |
Keybioscience Ag |
Acylated calcitonin mimetics
|
EA202190532A1
(ru)
|
2018-08-22 |
2021-07-08 |
Астразенека Аб |
Ингибиторы аргиназы и способы их применения
|
AR116315A1
(es)
*
|
2018-09-12 |
2021-04-21 |
Dizal Jiangsu Pharmaceutical Co Ltd |
Compuestos de triazolo-pirimidina y usos de los mismos
|
JP2022503792A
(ja)
|
2018-09-26 |
2022-01-12 |
クラ オンコロジー,インク. |
メニン阻害剤を用いた血液悪性腫瘍の処置
|
CN111295384B
(zh)
|
2018-10-10 |
2022-08-12 |
江苏豪森药业集团有限公司 |
双环类衍生物抑制剂、其制备方法和应用
|
AR117188A1
(es)
|
2018-11-02 |
2021-07-21 |
Aicuris Gmbh & Co Kg |
Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (vhb)
|
US20220040184A1
(en)
|
2018-11-20 |
2022-02-10 |
Merck Sharp Dohme Corp. |
Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
|
EP3889152A4
(en)
|
2018-11-30 |
2022-09-07 |
Jiangsu Hansoh Pharmaceutical Group Co., Ltd. |
HETEROAROMATIC DERIVATIVES FOR USE AS REGULATORS, PROCESS FOR THEIR PREPARATION AND THEIR USE
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
|
TW202115059A
(zh)
|
2019-08-09 |
2021-04-16 |
美商英塞特公司 |
Pd—1/pd—l1抑制劑之鹽
|
CA3150766A1
(en)
|
2019-08-26 |
2021-03-04 |
Incyte Corporation |
Triazolopyrimidines as a2a / a2b inhibitors
|
US11401279B2
(en)
|
2019-09-30 |
2022-08-02 |
Incyte Corporation |
Pyrido[3,2-d]pyrimidine compounds as immunomodulators
|
CR20220237A
(es)
|
2019-11-11 |
2022-08-05 |
Incyte Corp |
Sales y formas cristalinas de un inhibidor de pd-1/pd-l1
|
EP4085060A1
(en)
|
2020-01-03 |
2022-11-09 |
Incyte Corporation |
Combination therapy comprising a2a/a2b and pd-1/pd-l1 inhibitors
|
MX2022007575A
(es)
|
2020-01-03 |
2022-09-23 |
Incyte Corp |
Anticuerpos anti cumulo de diferenciacion 73 (cd73) y usos de estos.
|
KR20230117573A
(ko)
|
2020-11-06 |
2023-08-08 |
인사이트 코포레이션 |
Pd-1 및 pd-l1 억제제, 및 이의 염 및 결정형의 제조 방법
|
TW202233615A
(zh)
|
2020-11-06 |
2022-09-01 |
美商英塞特公司 |
Pd—1/pd—l1抑制劑之結晶形式
|
US11780836B2
(en)
|
2020-11-06 |
2023-10-10 |
Incyte Corporation |
Process of preparing a PD-1/PD-L1 inhibitor
|
JP2024502005A
(ja)
|
2020-12-29 |
2024-01-17 |
インサイト・コーポレイション |
A2a/a2b阻害剤、pd-1/pd-l1阻害剤、及び抗cd73抗体を含む併用療法
|